RhoVac ApS | LinkedIn
  • enEnglish
  • svSvenska
  • Home
  • About Us
    ▼
    • About Chosa Oncology
    • Board of Directors
    • Team
    • Vision and strategy
  • Product
    ▲
    • iCIP™
    • LiPlaCis®
    • DRP®
    • Scientific Articles
    • Patents
  • Investors
    ▼
    • Financial Reports
      ▼
      • Chosa Oncology
      • Rhovac
    • Presentations
    • Share Information
    • Event calendar
    • Corporate governance
  • News
    ▼
    • News
    • Subscribe
  • Contact
RhoVac AB - Logotype
  • Home
  • About Us
    • About Chosa Oncology
    • Board of Directors
    • Team
    • Vision and strategy
  • Product
    • iCIP™
    • LiPlaCis®
    • DRP®
    • Scientific Articles
    • Patents
  • Investors
    • Financial Reports
      • Chosa Oncology
      • Rhovac
    • Presentations
    • Share Information
    • Event calendar
    • Corporate governance
  • News
    • News
    • Subscribe
  • Contact
  • RHOVAC 1.27 (-0.02)

Product

  • iCIP™
  • LiPlaCis®
  • DRP®
  • Scientific Articles
  • Patents

Scientific Articles

 

Kappel Buhl, I. et al.
Molecular prediction of adjuvant cisplatin efficacy in Non-Small Cell Lung Cancer (NSCLC)—validation in two independent cohorts
PloS One 2018; 10.1371

Hugger Jacobsen, E et. al.
Liposomal cisplatin response prediction in heavily pretreated breast cancer patients: A multigene biomarker in a prospective phase 2 study
Journal of Clinical Oncology, 2018, e13077

Kappel Buhl, I. et. al.
Prospective blinded evaluation predicting efficacy of adjuvant cisplatinum and vinorelbine by a multigene assay after radical surgery in non-small cell lung cancer
Abstract no.: e20007, ASCO Annual Meeting, Chicago, 2016

Lassen et. al.
Abstract CT154: Phase I dose-escalating PoC study to evaluate the safety and tolerability of LiPlaCis (liposomal cisplatin formulation) in patients with advanced or refractory tumor
Cancer Research 76 (14 supplement), July 2016

 


Contact

Visiting address: Medicon Village, Scheeletorget 1, Lund, Sweden | Postal address: Medicon Village AB, SE-223 81 Lund, Sweden | Org.no: 559037-2271

+46 73-751 72 78 info@chosa.bio


RhoVac has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement No 879817.


Cookie Policy © 2015-2023 Chosa Oncology AB All rights reserved